Gastroenterology (GI)

Anusha Shirwaikar Thomas; Yinghong Wang

doi:10.1007/978-3-031-00241-0_5

Gastroenterology (GI)

Anusha Shirwaikar Thomas, Yinghong Wang

Gastroenterology Hepatology & Nutrition

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Immune checkpoint inhibitor (ICI) blockade has revolutionized the management, outcomes, and survival rates in advanced malignancies. However, the use of these immunotherapeutic agents comes with the risk of toxicities, namely, immune-related adverse events (irAEs). Toxicities involving the gastrointestinal (GI) tract are frequent and vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely clinical, biochemical, imaging, endoscopic, and histologic evaluation is key to ensure efficacious management and favorable outcomes. The severity of these toxicities drives management which comprises supportive care in mild disease and selective immunosuppressive therapy (SIT, infliximab or vedolizumab) in aggressive cases.

Original language	English (US)
Title of host publication	Managing Immunotherapy Related Organ Toxicities
Subtitle of host publication	A Practical Guide
Publisher	Springer International Publishing
Pages	81-96
Number of pages	16
ISBN (Electronic)	9783031002410
ISBN (Print)	9783031002403
DOIs	https://doi.org/10.1007/978-3-031-00241-0_5
State	Published - Jan 1 2022

Keywords

Colitis
Diarrhea
Enterocolitis
Gastrointestinal adverse events
Immune checkpoint inhibitors
Immunotherapy

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

Access to Document

10.1007/978-3-031-00241-0_5

Cite this

@inbook{4c8a472319ba421bb95a96203026e0e6,

title = "Gastroenterology (GI)",

abstract = "Immune checkpoint inhibitor (ICI) blockade has revolutionized the management, outcomes, and survival rates in advanced malignancies. However, the use of these immunotherapeutic agents comes with the risk of toxicities, namely, immune-related adverse events (irAEs). Toxicities involving the gastrointestinal (GI) tract are frequent and vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely clinical, biochemical, imaging, endoscopic, and histologic evaluation is key to ensure efficacious management and favorable outcomes. The severity of these toxicities drives management which comprises supportive care in mild disease and selective immunosuppressive therapy (SIT, infliximab or vedolizumab) in aggressive cases.",

keywords = "Colitis, Diarrhea, Enterocolitis, Gastrointestinal adverse events, Immune checkpoint inhibitors, Immunotherapy",

author = "{Shirwaikar Thomas}, Anusha and Yinghong Wang",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-00241-0_5",

language = "English (US)",

isbn = "9783031002403",

pages = "81--96",

booktitle = "Managing Immunotherapy Related Organ Toxicities",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Gastroenterology (GI)

AU - Shirwaikar Thomas, Anusha

AU - Wang, Yinghong

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Immune checkpoint inhibitor (ICI) blockade has revolutionized the management, outcomes, and survival rates in advanced malignancies. However, the use of these immunotherapeutic agents comes with the risk of toxicities, namely, immune-related adverse events (irAEs). Toxicities involving the gastrointestinal (GI) tract are frequent and vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely clinical, biochemical, imaging, endoscopic, and histologic evaluation is key to ensure efficacious management and favorable outcomes. The severity of these toxicities drives management which comprises supportive care in mild disease and selective immunosuppressive therapy (SIT, infliximab or vedolizumab) in aggressive cases.

AB - Immune checkpoint inhibitor (ICI) blockade has revolutionized the management, outcomes, and survival rates in advanced malignancies. However, the use of these immunotherapeutic agents comes with the risk of toxicities, namely, immune-related adverse events (irAEs). Toxicities involving the gastrointestinal (GI) tract are frequent and vary in severity from mild disease to aggressive life-threatening clinical presentations. Timely clinical, biochemical, imaging, endoscopic, and histologic evaluation is key to ensure efficacious management and favorable outcomes. The severity of these toxicities drives management which comprises supportive care in mild disease and selective immunosuppressive therapy (SIT, infliximab or vedolizumab) in aggressive cases.

KW - Colitis

KW - Diarrhea

KW - Enterocolitis

KW - Gastrointestinal adverse events

KW - Immune checkpoint inhibitors

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85163563048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163563048&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-00241-0_5

DO - 10.1007/978-3-031-00241-0_5

M3 - Chapter

AN - SCOPUS:85163563048

SN - 9783031002403

SP - 81

EP - 96

BT - Managing Immunotherapy Related Organ Toxicities

PB - Springer International Publishing

ER -

Gastroenterology (GI)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this